Valuation: TransMedics Group, Inc.

Market Cap 228.82Cr 204.93Cr 188.51Cr 170.8Cr 319.27Cr 22TCr 325.25Cr 2.25TCr 902.4Cr 11TCr 858.74Cr 840.48Cr 36TCr P/E 2026 *
49.4x
P/E 2027 * 30.2x
Enterprise Value 224.8Cr 201.33Cr 185.19Cr 167.8Cr 313.65Cr 21TCr 319.52Cr 2.21TCr 886.53Cr 11TCr 843.63Cr 825.7Cr 35TCr EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.45x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week-6.71%
1 month-20.92%
3 months-13.75%
6 months-34.53%
Current year-45.75%
1 week 64.64
Extreme 64.64
71.97
1 month 64.64
Extreme 64.64
84.05
Current year 60.1
Extreme 60.105
151.85
1 year 60.1
Extreme 60.105
156
3 years 38.13
Extreme 38.13
177.37
5 years 10
Extreme 10
177.37
10 years 10
Extreme 10
177.37
Manager TitleAgeSince
Chief Executive Officer 57 01/08/1998
Director of Finance/CFO 46 21/09/2026
Chief Operating Officer 43 02/02/2023
Director TitleAgeSince
Director/Board Member 57 01/08/1998
Chairman 81 01/01/2011
Director/Board Member 78 01/02/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/09/26 Buy

Director

1,336 0.0039%
17/08/26 Don

Chairman

-18,000 0.0528%
10/07/26 Free

Chief Financial Officer

43,399 0.1273%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-6.71%-49.83%+76.07% 228.82Cr
-1.72%+3.44%+22.84%+56.71% 26TCr
-2.00%+0.75%+7.82%+20.94% 16TCr
-3.73%-4.48%-19.14%+64.75% 15TCr
-1.66%-8.12%-58.32%-17.99% 6.08TCr
-.--%+2.46%-11.69%-7.41% 5.33TCr
-2.57%+3.30%+11.59%+44.40% 5.3TCr
+0.84%-3.12%+7.47%+62.40% 5.07TCr
-3.47%+1.04%+19.48%+69.17% 4.93TCr
-3.61%+1.99%+32.36%+93.99% 4.55TCr
Average -1.96%-0.94%-3.74%+46.30% 8.86TCr
Weighted average by Cap. -2.10%+0.14%+3.89%+44.73%

Financials

2026 *2027 *
Net sales 74Cr 66Cr 61Cr 55Cr 103.56Cr 7.05TCr 105.49Cr 729.12Cr 292.69Cr 3.71TCr 278.53Cr 272.61Cr 12TCr 87Cr 78Cr 72Cr 65Cr 122.04Cr 8.31TCr 124.33Cr 859.3Cr 344.95Cr 4.37TCr 328.26Cr 321.28Cr 14TCr
Net income 5.09Cr 4.55Cr 4.19Cr 3.8Cr 7.1Cr 482.91Cr 7.23Cr 50Cr 20Cr 254.02Cr 19Cr 19Cr 801.1Cr 8.8Cr 7.89Cr 7.25Cr 6.57Cr 12Cr 835.98Cr 13Cr 86Cr 35Cr 439.75Cr 33Cr 32Cr 1.39TCr
Net Debt -4.03Cr -3.61Cr -3.32Cr -3.01Cr -5.62Cr -382.26Cr -5.72Cr -40Cr -16Cr -201.08Cr -15Cr -15Cr -634.13Cr -15Cr -13Cr -12Cr -11Cr -20Cr -1.38TCr -21Cr -143.09Cr -57Cr -727.48Cr -55Cr -53Cr -2.29TCr
Projected Income Statement - Annual - TransMedics Group, Inc.
Logo TransMedics Group, Inc.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Employees
898
Date Price Change Volume
30/26/30 $65.99 -1.68% 9,00,109
29/26/29 $67.12 +0.33% 9,91,426
28/26/28 $66.90 -4.06% 11,83,676
27/26/27 $69.73 -1.27% 8,26,605
26/26/26 $70.63 -0.16% 8,47,927
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - TransMedics Group, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
65.99USD
Average target price
98.73USD
Spread / Average Target
+49.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TransMedics Group, Inc.
  1. Stock Market
  2. Stocks
  3. TMDX Stock